Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):314–320. doi: 10.1158/1055-9965.EPI-08-0627

Table 4.

Urinary isothiocyanates in relation to risk of colorectal cancer by GST genotypes

Cases n (%) Controls n (%) Crude OR*(95% CI) Adjusted OR (95% CI) P for interaction
GSTM1
  GSTM1 non-null, undetectable ITC 19 (23) 31 (19) 1.00 1.00
  GSTM1 non-null, detectable ITC 63 (77) 135 (81) 0.59 (0.25–1.39) 0.49 (0.19–1.25)
  GSTM1 null, undetectable ITC 23 (25) 26 (18) 1.00 1.00
  GSTM1 null, detectable ITC 68 (75) 121 (82) 0.56 (0.21–1.46) 0.53 (0.15–1.93) 0.42
GSTT1
  GSTT1 non-null, undetectable ITC 32 (25) 39 (19) 1.00 1.00
  GSTT1 non-null, detectable ITC 95 (75) 162 (81) 0.63 (0.33–1.20) 0.56 (0.28–1.13)
  GSTT1 null, undetectable ITC 10 (22) 18 (16) 1.00 1.00
  GSTT1 null, detectable ITC 36 (78) 94 (84) 1.07 (0.32–3.57) 0.86 (0.17–4.43) 0.36
GSTP1
  GSTP1 AA, undetectable ITC 21 (21) 24 (15) 1.00 1.00
  GSTP1 AA, detectable ITC 78 (79) 138 (85) 0.53 (0.22–1.30) 0.58 (0.22–1.48)
  GSTP1 AG/GG, undetectable ITC 21 (28) z33 (22) 1.00 1.00
  GSTP1 AG/GG, detectable ITC 53 (72) 118 (78) 0.57 (0.25–1.31) 0.47 (0.19–1.17) 0.09
*

Based on conditional logistic regression, using matched sets as strata.

Further adjusted for age at blood draw, hours of fasting before blood draw, processed meat (density, g/kcal/d), ethanol (g/d), obesity, and history of colorectal cancer screening.

Values based on adjusted models, with urinary isothiocyanates, adjusted for creatinine, as a continuous variable.